Author: Gumilang, Rizki A.; Siswanto,; Anggraeni, Vita Y.; Trisnawati, Ika; Budiono, Eko; Hartopo, Anggoro B.
Title: QT interval and repolarization dispersion changes during the administration of hydroxychloroquine/chloroquine with/without azithromycin in early COVID 19 pandemic: A prospective observational study from two academic hospitals in Indonesia Cord-id: b8r6jwer Document date: 2021_8_28
ID: b8r6jwer
Snippet: BACKGROUND: Hydroxychloroquine/chloroquine (HCQ/CQ) treatment for COVIDâ€19 was associated with QT interval prolongation and arrhythmia risks. This study aimed to investigate QTc interval and ventricular repolarization dispersion changes, as markers of arrhythmia risks, after HCQ/CQ administration with/without azithromycin (AZT) during COVIDâ€19 pandemic. METHODS: A prospective observational study was performed in two academic hospitals in Indonesia. Adult patients who received HCQ/CQ alone an
Document: BACKGROUND: Hydroxychloroquine/chloroquine (HCQ/CQ) treatment for COVIDâ€19 was associated with QT interval prolongation and arrhythmia risks. This study aimed to investigate QTc interval and ventricular repolarization dispersion changes, as markers of arrhythmia risks, after HCQ/CQ administration with/without azithromycin (AZT) during COVIDâ€19 pandemic. METHODS: A prospective observational study was performed in two academic hospitals in Indonesia. Adult patients who received HCQ/CQ alone and HCQ/CQ + AZT concomitant treatments for COVIDâ€19 infection were enrolled. Baseline and post HCQ/CQ treatment electrocardiograms were obtained. Baseline and post HCQ/CQ treatment QT interval by Bazett (Bâ€QTc) and Fridericia (Fâ€QTc) formulas and ventricular repolarization dispersion indices by Tpeakâ€Tend (Tpâ€e) interval and Tpeakâ€Tend/QT (Tpâ€e/QT) ratio were calculated and analyzed. RESULTS: The study enrolled 55 (HCQ/CQ alone) and 77 subjects (HCQ/CQ + AZT concomitant). Fâ€QTc interval significantly lengthened in subjects with HCQ/CQ + AZT (mean difference 11.89 ms [P = .028]). The incidences of severe Bâ€QTc and Fâ€QTc lengthening were 13.1% and 12.3%, Bâ€QTc and Fâ€QTc prolongation were 25.4% and 12.3%, and severe Bâ€QTc and Fâ€QTc prolongation were 6.2% and 3.2%. Tpâ€e interval lengthened significantly from baseline to posttreatment in HCQ/CQ alone and HCQ/CQ + AZT (mean difference 10.83 ms [P = .006] and 18.73 ms [P < .001], respectively). Tpâ€e/QT ratio increased significantly from baseline to posttreatment in HCQ/CQ + AZT concomitant (mean difference 0.035 [P < .001]). No fatal arrhytmia occurred. CONCLUSIONS: During COVIDâ€19 pandemic, HCQ/CQ + AZT concomitant treatment caused significant Fâ€QTc lengthening, significantly increased Tpâ€e interval and increased Tpâ€e/QT ratio. HCQ/CQ alone only caused significant increase of Tpâ€e interval. Incidences of severe QTc lengthening and prolongation were low in both HCQ/CQ alone and HCQ/CQ + AZT concomitant.
Search related documents:
Co phrase search for related documents, hyperlinks ordered by date